ProQR Announces Upcoming Investor Conferences in November and December
ProQR Therapeutics N.V. (Nasdaq: PRQR) has announced its participation in two upcoming investor conferences. The conferences include the Stifel 2021 Virtual Healthcare Conference on November 15 and the Evercore ISI 4th Annual HealthCONx Conference on December 2. Each session will feature a fireside chat with company management, offering insights into ProQR's innovative RNA therapies aimed at treating genetic eye diseases. Details will be available on ProQR's website, with archived webcasts accessible for 30 days post-event.
- None.
- None.
LEIDEN, Netherlands & CAMBRIDGE, Mass., Nov. 08, 2021 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (the “Company”), a company dedicated to changing lives through the creation of transformative RNA therapies for genetic eye diseases, today announced that Company management will participate in the following upcoming investor conferences:
- Stifel 2021 Virtual Healthcare Conference
Monday, November 15, 11:20-11:50am EST – Fireside chat - Evercore ISI 4th Annual HealthCONx Conference
Thursday, December 2, 9:40-10:00am EST – Fireside chat
Presentation and webcast details will be accessible from the “Investors & Media” section of ProQR’s website (www.proqr.com) under “Events”. Archived webcasts will be available for approximately 30 days following the presentation date.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the creation of transformative RNA therapies for the treatment of severe genetic rare diseases such as Leber congenital amaurosis 10, Usher syndrome and retinitis pigmentosa. Based on our unique proprietary RNA repair platform technologies we are growing our pipeline with patients and loved ones in mind.
Learn more about ProQR at www.proqr.com.
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as "anticipate," "believe," "could," "estimate," "expect," "goal," "intend," "look forward to", "may," "plan," "potential," "predict," "project," "should," "will," "would" and similar expressions. Such forward-looking statements include, but are not limited to, statements regarding our participation in these conferences. Forward-looking statements are based on management's beliefs and assumptions and on information available to management only as of the date of this press release. Our actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, the risks, uncertainties and other factors in our filings made with the Securities and Exchange Commission, including certain sections of our annual report filed on Form 20-F. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
ProQR Therapeutics N.V.
Investor Contact:
Sarah Kiely
ProQR Therapeutics N.V.
T: +1 617 599 6228
skiely@proqr.com
or
Hans Vitzthum
LifeSci Advisors
T: +1 617 430 7578
hans@lifesciadvisors.com
Media Contact:
Cherilyn Cecchini, MD
LifeSci Communications
T: +1 646 876 5196
ccecchini@lifescicomms.com
FAQ
What are the dates of the investor conferences for ProQR Therapeutics (PRQR)?
What is the focus of ProQR Therapeutics (PRQR) as mentioned in the press release?
Where can I watch the presentations from ProQR Therapeutics (PRQR) investor conferences?
What type of therapies does ProQR Therapeutics (PRQR) develop?
